Quick Take
Sun BioPharma (SNBP) has filed to raise $12 million in an IPO of its common stock, according to an S-1 registration statement.
The firm is a clinical stage biopharma advancing a small molecule treatment candidate for pancreatic cancer and other solid tumors.
SNBP is a tiny firm with little capital trying to find a more effective treatment for a very difficult area of cancer research.
I'll provide an update when we learn more about the IPO.
Company & Technology
Waconia, Minnesota-based Sun was founded to develop a single polyamine metabolic inhibitor for patients